Last Update 17 Nov 25
Fair value Decreased 19%GOCO: Recent Credit Move Will Boost Flexibility Ahead of Enrollment Period
Analysts have revised GoHealth's fair value estimate downward from $17.20 to $14.00. This change is due to updated model assumptions and increased caution surrounding revenue growth following recent company results and financial transactions.
Analyst Commentary
Analysts have shared mixed perspectives following GoHealth's recent financial results and transactions. The shifts in price targets and ongoing sector performance evaluations reflect both opportunities and lingering uncertainties affecting the company's outlook.
Bullish Takeaways- Bullish analysts have responded positively to updated valuation models and have raised price targets in light of improved financial flexibility following recent credit transactions.
- The enhanced balance sheet is seen as strengthening GoHealth's ability to navigate the upcoming Annual Enrollment Period, a critical timeframe for driving revenue growth.
- The added capacity from credit agreements is viewed as creating potential for future mergers and acquisitions, which could expand the company's service offerings and market presence.
- Some analysts remain cautious due to ongoing uncertainty in revenue growth, especially as the company integrates recent changes and prepares for significant enrollment periods.
- Execution risks persist, with the need to demonstrate tangible growth and operational improvements in the next quarters to meet revised valuation expectations.
- There is increased scrutiny on whether the company can leverage its enhanced flexibility effectively, especially in the context of broader industry and macroeconomic headwinds.
What's in the News
- GoHealth continues to deploy proprietary PlanFit technology, enabling licensed insurance agents to offer comprehensive, personalized guidance as Medicare consumers face fewer choices and increased uncertainty during this year's Annual Enrollment Period (Key Developments).
- The recent introduction of PlanFit CheckUp provides consumers with an annual review to compare available options to their current Medicare plan, supporting better decision-making and plan satisfaction (Key Developments).
- GoHealth's AI-powered tool, PlanGPT, has reduced the average call time for plan comparison by 10 minutes in 2024. This improvement allows agents to provide more efficient, personalized service (Key Developments).
- During the last Annual Enrollment Period, GoHealth helped nearly 30,000 consumers confirm that their current plan was still the best fit option, despite unprecedented market disruption (Key Developments).
- Medicare beneficiaries are advised to think SMART and seek reliable guidance from licensed professionals to navigate significant changes, including plan exits and degradation affecting millions of enrollees (Key Developments).
Valuation Changes
- Fair Value Estimate has decreased from $17.20 to $14.00. This reflects a sizable downward revision based on updated assumptions.
- Discount Rate has risen slightly from 12.32 percent to 12.5 percent, which signals a modest increase in perceived risk.
- Revenue Growth projections have shifted from an expected increase of 3.40 percent to a decline of 1.40 percent. This indicates a notably more cautious outlook.
- Net Profit Margin forecast has edged down marginally from 11.07 percent to 11.02 percent.
- Future Price-to-Earnings (P/E) ratio is now projected at 4.85x, down from 8.48x previously. This suggests lower expected earnings growth and valuation multiples.
Key Takeaways
- Improved financial flexibility and strategic focus enable investment in technology, product expansion, and acquisitions, supporting future revenue growth and margin improvement.
- Diversification into life insurance and enhanced tech capabilities boost efficiency, reduce earnings volatility, and position the company to capture greater market share.
- Heavy reliance on debt, share dilution, and challenging acquisitions amid regulatory and market uncertainty heighten risks to sustainable growth and long-term value stability.
Catalysts
About GoHealth- Operates as a health insurance marketplace and Medicare-focused digital health company in the United States.
- The newly secured $115 million term loan facility, along with covenant relief and maturity extensions, grants GoHealth significant financial flexibility and removes immediate going concern issues, enabling proactive investment in technology, product growth, and M&A-positioning the company for revenue growth and improved net margins over the medium term.
- The company's ability to actively pursue strategic acquisitions in a fragmented Medicare and senior health marketplace-with up to $250 million of lender-approved deal capacity and an empowered Transformation Committee-positions GoHealth to capture greater market share and drive scale-driven operating leverage, benefitting both revenue and margins.
- Deployment and scaling of the GoHealth Protect (final expense/life insurance) product suite diversifies revenue sources beyond Medicare Advantage, reducing earnings volatility and creating new cross-sell opportunities-expected to support incremental revenue growth and margin stabilization as the digitalization of healthcare shopping accelerates.
- Enhanced technology and data-driven supply/demand matching are enabling higher agent productivity and operational efficiency, which should allow for lower cost per acquisition and higher lead-to-policy conversion rates-supporting future earnings and margin expansion as consumer reliance on advisory platforms increases due to rising healthcare complexity.
- GoHealth remains structurally levered to ongoing demographic aging and heightened regulatory/benefit disruption in core Medicare markets, creating sustained demand for unbiased, tech-enabled plan selection platforms-likely to translate into persistent customer acquisition opportunities and long-term top-line growth.
GoHealth Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming GoHealth's revenue will grow by 3.4% annually over the next 3 years.
- Analysts are not forecasting that GoHealth will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate GoHealth's profit margin will increase from -3.7% to the average US Insurance industry of 11.1% in 3 years.
- If GoHealth's profit margin were to converge on the industry average, you could expect earnings to reach $100.6 million (and earnings per share of $2.87) by about September 2028, up from $-30.2 million today.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 8.5x on those 2028 earnings, up from -2.6x today. This future PE is lower than the current PE for the US Insurance industry at 14.6x.
- Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 12.32%, as per the Simply Wall St company report.
GoHealth Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- GoHealth's recent issuance of significant equity to lenders as part of the new debt facility leads to share dilution, directly impacting per-share earnings and potentially limiting share price appreciation for existing shareholders despite operational improvements.
- The company is undergoing an intangible asset impairment, indicative of prior overvaluation of assets or underperformance in acquired businesses; this raises concerns over GoHealth's ability to accurately forecast and deliver sustained value from acquisitions, increasing volatility and uncertainty in long-term earnings and revenue streams.
- While GoHealth has secured a temporary covenant holiday and capital runway, its reliance on debt financing with high interest rates (SOFR + 550 bps) raises longer-term financial risk and higher interest expenses, which can compress net margins and reduce future profitability.
- GoHealth's strategy to focus more intensely on industry consolidation and M&A, while potentially accretive, exposes it to substantial execution risk and integration challenges-if acquisitions fail to deliver expected synergies or results, this could hinder revenue growth and margin expansion.
- The company's substantial pullback from Medicare Advantage activity in response to health plan uncertainty, along with ongoing regulatory and market disruptions, highlights its sensitivity to external factors (like plan benefit changes and regulatory shifts), which could further impact customer acquisition, retention, and revenue predictability going forward.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $17.2 for GoHealth based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $22.0, and the most bearish reporting a price target of just $12.0.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $909.1 million, earnings will come to $100.6 million, and it would be trading on a PE ratio of 8.5x, assuming you use a discount rate of 12.3%.
- Given the current share price of $4.84, the analyst price target of $17.2 is 71.9% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.


